{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:22:54Z","timestamp":1791206574552,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T00:00:00Z","timestamp":1714176000000},"content-version":"am","delay-in-days":301,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.ejca.2023.03.037","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T17:17:27Z","timestamp":1680715047000},"page":"58-64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Neo-Adjuvant immunotherapies: Bladder cancer as a platform for drug development targeting mucosal immunity"],"prefix":"10.1016","volume":"187","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5916-0477","authenticated-orcid":false,"given":"Rainjade","family":"Chung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"McKiernan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Arpaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Marabelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2970-4821","authenticated-orcid":false,"given":"Mathieu","family":"Rouanne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2023.03.037_bib1","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1038\/s41385-022-00565-0","article-title":"The urothelium: a multi-faceted barrier against a harsh environment","volume":"15","author":"Jafari","year":"2022","journal-title":"Mucosal Immunol"},{"issue":"9","key":"10.1016\/j.ejca.2023.03.037_bib2","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41585-022-00608-y","article-title":"The dynamic roles of the bladder tumour microenvironment","volume":"19","author":"Lee","year":"2022","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.ejca.2023.03.037_bib3","doi-asserted-by":"crossref","unstructured":"Goubet A.G., Rouanne M., Derosa L., et al. From mucosal infection to successful cancer immunotherapy. Nat Rev Urol. 2023 (in press).","DOI":"10.1038\/s41585-023-00784-5"},{"issue":"3","key":"10.1016\/j.ejca.2023.03.037_bib4","first-page":"359","article-title":"Therapeutic options in high-risk non-muscle-invasive bladder cancer during the current worldwide shortage of bacille calmette-gu\u00e9rin","volume":"67","author":"Mostafid","year":"2015","journal-title":"Eur\u00a0Urol"},{"issue":"6","key":"10.1016\/j.ejca.2023.03.037_bib5","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.eururo.2022.08.004","article-title":"First-in-human intravesical delivery of pembrolizumab identifies immune activation in bladder cancer unresponsive to Bacillus Calmette-Gu\u00e9rin","volume":"82","author":"Meghani","year":"2022","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ejca.2023.03.037_bib6","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1001\/jamaoncol.2020.6142","article-title":"Pembrolizumab for non-muscle-invasive bladder cancer-a costly therapy in search of evidence","volume":"7","author":"Gill","year":"2021","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2023.03.037_bib7","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200167","article-title":"IL-15 superagonist NAI in BCG-unresponsive non\u2013muscle-invasive bladder cancer","volume":"2","author":"Chamie","year":"2023","journal-title":"NEJM Evid"},{"issue":"6","key":"10.1016\/j.ejca.2023.03.037_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096705","article-title":"Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion","volume":"9","author":"Gomes-Giacoia","year":"2014","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.ejca.2023.03.037_bib9","doi-asserted-by":"crossref","DOI":"10.1172\/JCI145666","article-title":"BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancer","volume":"132","author":"Rouanne","year":"2022","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.ejca.2023.03.037_bib10","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2023.03.037_bib11","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.eururo.2021.12.009","article-title":"Antiadenovirus antibodies predict response durability to nadofaragene firadenovec therapy in BCG-unresponsive non-muscle-invasive bladder cancer: secondary analysis of a phase 3 clinical trial","volume":"81","author":"Mitra","year":"2022","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.ejca.2023.03.037_bib12","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41585-021-00483-z","article-title":"Using oncolytic viruses to ignite the tumour immune microenvironment in bladder cancer","volume":"18","author":"Li","year":"2021","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.ejca.2023.03.037_bib13","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejca.2021.04.035","article-title":"Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: The future is now!","volume":"152","author":"Maio","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.03.037_bib14","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejca.2023.01.004","article-title":"Neo-adjuvant immunotherapy emerges as best medical practice, and will be the new standard of care for macroscopic stage III melanoma","volume":"182","author":"van Akkooi","year":"2023","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2023.03.037_bib15","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European Association of Urology Guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.ejca.2023.03.037_bib16","doi-asserted-by":"crossref","first-page":"866","DOI":"10.6004\/jnccn.2022.0041","article-title":"NCCN Guidelines\u00ae Insights: Bladder Cancer, Version 2.2022","volume":"20","author":"Flaig","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"10.1016\/j.ejca.2023.03.037_bib17","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.juro.2017.04.086","article-title":"Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/ASTRO\/SUO Guideline","volume":"198","author":"Chang","year":"2017","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.ejca.2023.03.037_bib18","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.euo.2020.06.009","article-title":"Rationale and outcomes for neoadjuvant immunotherapy in urothelial carcinoma of the bladder","volume":"3","author":"Rouanne","year":"2020","journal-title":"Eur Urol Oncol"},{"issue":"34","key":"10.1016\/j.ejca.2023.03.037_bib19","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1200\/JCO.18.01148","article-title":"Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase ii study","volume":"36","author":"Necchi","year":"2018","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.ejca.2023.03.037_bib20","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1158\/1078-0432.CCR-22-2158","article-title":"Neoadjuvant pembrolizumab and radical cystectomy in patients with muscle-invasive urothelial bladder cancer: 3-year median follow-up update of PURE-01 trial","volume":"28","author":"Basile","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.ejca.2023.03.037_bib21","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","article-title":"Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial","volume":"25","author":"Powles","year":"2019","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.ejca.2023.03.037_bib22","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.eururo.2022.04.013","article-title":"Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder","volume":"82","author":"Szabados","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2023.03.037_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-022-02199-y","article-title":"High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial","author":"van Dorp","year":"2023","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.ejca.2023.03.037_bib24","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1038\/s41591-020-1085-z","article-title":"Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial","volume":"26","author":"van Dijk","year":"2020","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.ejca.2023.03.037_bib25","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1038\/s41591-020-1086-y","article-title":"Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma","volume":"26","author":"Gao","year":"2020","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.ejca.2023.03.037_bib26","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1158\/2159-8290.CD-22-0201","article-title":"Escherichia coli-specific CXCL13-producing TFH are associated with clinical efficacy of neoadjuvant PD-1 blockade against muscle-invasive bladder","volume":"12","author":"Goubet","year":"2022","journal-title":"Cancer Discov"},{"issue":"9","key":"10.1016\/j.ejca.2023.03.037_bib27","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41571-021-00507-y","article-title":"Intratumoural administration and tumour tissue targeting of cancer immunotherapies","volume":"18","author":"Melero","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2023.03.037_bib28","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.ejca.2021.08.004","article-title":"Current strategies for intratumoural immunotherapy - beyond immune checkpoint inhibition","volume":"157","author":"Yuan","year":"2021","journal-title":"Eur J Cancer"},{"issue":"16_suppl 4574-4574","key":"10.1016\/j.ejca.2023.03.037_bib29","article-title":"Preliminary results from phase Ib\/II neoadjuvant CG0070 and nivolumab (N) for cisplatin (C)-ineligible muscle invasive bladder cancer (MIBC)","volume":"40","author":"Li","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.ejca.2023.03.037_bib30","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS584","article-title":"SunRISe-4: TAR-200 plus cetrelimab or cetrelimab alone as neoadjuvant therapy in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or refuse neoadjuvant platinum-based chemotherapy","volume":"41","author":"Psutka","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923001739?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923001739?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:40:43Z","timestamp":1760733643000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923001739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":30,"alternative-id":["S0959804923001739"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.03.037","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neo-Adjuvant immunotherapies: Bladder cancer as a platform for drug development targeting mucosal immunity","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.03.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}